Breaking barriers in HIV treatment: the game-changing impact of lenacapavir-Reference-Cited by-同舟云学术

Breaking barriers in HIV treatment: the game-changing impact of lenacapavir

Published:2023-12-22 Issue:1 Volume:10 Page:32-33
ISSN:2454-2164
Container-title:International Journal of Scientific Reports
language:
Short-container-title:Int J Sci Rep

Author:

Mukhtar Sameen,Haris Muhammad

Abstract

HIV is a lentivirus that selectively targets and infects CD4 cells, which are integral to the immune system. Through viral integration and replication, infected cells are gradually destroyed, leading to a weakened immune system and an increased susceptibility to illnesses. The HIV epidemic has resulted in approximately 40.1 million deaths and 84.2 million infections to date, with 38.4 million individuals living with HIV as of the end of 2021. The estimated global prevalence of HIV in adults aged 15 to 49 is 0.7%.

Publisher

Medip Academy

Subject

General Medicine

Reference6 articles.

1. WebMD. How to Treat HIV, 2023. Available at: https://www.webmd.com/hivaids/understandingaids-hiv-treatment#091e9c5e80008962-1-3. Accessed on 01 October 2023.

2. Sunlenca. SUNLENCA® Was Granted FDA Breakthrough Therapy Designation and Has a Novel MOA1,2, 2023. Available at: https://www. sunlencahcp.com/howsunlencaworks/first-in-class-moa/. Accessed on 01 October 2023.

3. Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17(1):15-21.

4. Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigatoet alrs. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386(19):1793-803.

5. REUTERS. U.S. FDA approves Gilead's long-acting HIV drug Sunlenca, 2023. Available at: https://www.reuters.com/business/healthcarlongacting-hiv-drug-sunlenca-2022-12-22/. Accessed on 01 October 2023.